Xencor Inc (XNCR.OQ)
29.15USD
4:00pm EDT
$-0.73 (-2.44%)
$29.88
$29.87
$30.10
$29.05
67,247
108,005
$34.62
$18.67
About
Overall
| Beta: | 1.48 |
| Market Cap(Mil.): | $1,622.56 |
| Shares Outstanding(Mil.): | 54.30 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| XNCR.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 188.22 | 33.60 |
| EPS (TTM): | -1.05 | -- | -- |
| ROI: | -16.01 | -0.74 | 13.19 |
| ROE: | -16.42 | -2.80 | 15.00 |
BRIEF-Xencor Says Public Offering Of 7.30 Mln Common Shares Priced At $31 Per Share
* XENCOR ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
BRIEF-Xencor Files For Potential Mixed Shelf Offering
* XENCOR INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text: (http://bit.ly/2G8MdV1) Further company coverage:
BRIEF-Xencor Announces Proposed Public Offering Of Common Stock
* XENCOR, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
BRIEF-Xencor Reports Q4 Loss Per Share $0.25
* XENCOR REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
BRIEF-Xencor Doses First Patient In Phase 1 Study Of Xmab®18087,An Antibody For Treatment Of Neuroendocrine Tumors And Gastrointestinal Stromal Tumors
* XENCOR DOSES FIRST PATIENT IN PHASE 1 STUDY OF XMAB®18087 BISPECIFIC TUMOR TARGETING ANTIBODY FOR THE TREATMENT OF NEUROENDOCRINE TUMORS AND GASTROINTESTINAL STROMAL TUMORS
BRIEF-Xencor Inc - Expect Initial Data From Phase 2 Trial Of Xmab®5871 In Systemic Lupus Erythematosus
* XENCOR INC - EXPECT INITIAL DATA FROM PHASE 2 TRIAL OF XMAB®5871 IN SYSTEMIC LUPUS ERYTHEMATOSUS
BRIEF-Xencor Receives Milestone Payment From Amgen
* SAYS IT HAS EARNED A $10 MILLION MILESTONE PAYMENT FROM AMGEN
BRIEF-Xencor posts Q3 loss of $0.33 per share
* Xencor reports third quarter 2017 financial results and provides clinical pipeline update
Competitors
| Price | Chg | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $36.80 | +0.17 |
| Novartis AG (NOVN.S) | CHF76.04 | -0.04 |
| Roche Holding Ltd. (ROG.S) | CHF217.60 | +1.95 |
| Roche Holding Ltd. (RO.S) | CHF221.40 | +1.40 |
| AstraZeneca plc (AZN.L) | 5,015.00 | +39.00 |
| GlaxoSmithKline plc (GSK.L) | 1,445.00 | +15.00 |
| AbbVie Inc (ABBV.N) | $93.17 | +0.57 |
| Bristol-Myers Squibb Co (BMY.N) | $50.90 | -0.27 |
| Bristol-Myers Squibb Co (BMYMP.PK) | $1,306.55 | -- |
| Amgen, Inc. (AMGN.OQ) | $174.66 | +3.10 |
Estimates